Ptc Therapeutics (PTCT) Cash & Equivalents (2012 - 2026)

Ptc Therapeutics' Cash & Equivalents history runs 15 years deep, the most recent figure standing at $834.0 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 43.66% year-over-year to $834.0 million; the TTM figure through Mar 2026 stood at $834.0 million (down 43.66% YoY), while the FY2025 annual figure was $984.6 million, up 26.28% from the prior year.
• Cash & Equivalents was $834.0 million for Q1 2026 at Ptc Therapeutics, down from $984.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $1.5 billion in Q1 2025 to a low of $104.4 million in Q3 2022.
• Historically, Cash & Equivalents has averaged $548.2 million across 5 years, with a median of $548.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents sank 44.99% in 2022, then jumped 227.39% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $279.8 million in 2022, then soared by 112.27% to $594.0 million in 2023, then jumped by 31.26% to $779.7 million in 2024, then rose by 26.28% to $984.6 million in 2025, then declined by 15.3% to $834.0 million in 2026.
• The last three Cash & Equivalents figures came in at $834.0 million (Q1 2026), $984.6 million (Q4 2025), and $672.6 million (Q3 2025), per Business Quant data.